Toboroz
A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants With Recurrent Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (LG-IR-NMIBC) From Study BL013
2026-526359-75-00· 4. fázis· Urogen Pharma Ltd.· Forrás
Még nem toboroz
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
NCT07757412· 2. fázis· Odense University Hospital· Forrás
Toboroz
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Effect on the tolerability of semaglutide in overweight adults without diabetes
2025-524612-11-00· 4. fázis· University Of Tartu· Forrás
Toboroz
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
2025-524575-22-00· 2/3. fázis· Eyebiotech Limited· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
NCT07216235· 3. fázis· Zydus Therapeutics Inc.· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás
Toboroz
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004· 3. fázis· argenx· Forrás
Toboroz
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Még nem toboroz
Sequential Chemotherapy regimen with vinorelbine and cisplatin plus PET-guided stereotactic ablative radiotherapy (SABR) for castration- and taxane-resistant Prostate cancer (ChemSABR Prostate)
2025-521551-23-01· 1/2. fázis· Tartu University Hospital· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Fut, nem toboroz
Polygenic Risk Driven Pragmatic Statin Trial for Heart Disease Prevention
NCT06820086· 4. fázis· Mikk JÜRISSON· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Toboroz
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· 3. fázis· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Toboroz
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· 2. fázis· Princess Maxima Center for Pediatric Oncology· Forrás
Fut, nem toboroz
LSTA1 for subjects with newly diagnosed Glioblastoma Multiforme when added to standard of care (temozolomide) versus temozolomide
2023-506813-23-00· 2. fázis· Tartu University Hospital· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00· 3. fázis· Prinses Maxima Centrum voor Kinderoncologie B.V.· Forrás
Fut, nem toboroz
Atacicept in Subjects With IgA Nephropathy
NCT04716231· 3. fázis· Vera Therapeutics, Inc.· Forrás
Fut, nem toboroz
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04628026· 3. fázis· University of Ulm· Forrás
Még nem toboroz
The usage of unenriched emulsified fat transplant in temporomandibular joint degenerative diseases
2024-520244-41-00· 2. fázis· Tartu University Hospital· Forrás
Fut, nem toboroz
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550· 3. fázis· UroGen Pharma Ltd.· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
NCT04332822· 3. fázis· Nordic Lymphoma Group· Forrás
Toboroz
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· 3. fázis· Mats Heyman· Forrás
Fut, nem toboroz
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200· 3. fázis· AstraZeneca· Forrás
Toboroz
Randomised Evaluation of COVID-19 Therapy
NCT04381936· 3. fázis· University of Oxford· Forrás
Toboroz
Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy
2024-517854-91-00· 3. fázis· Pirkanmaan hyvinvointialue· Forrás
Fut, nem toboroz
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS
2023-507906-15-00· 3. fázis· Novartis Pharma AG· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068· 3. fázis· AbbVie· Forrás